研究業績

2023

原著論文

  1. “Origin of the kinetic HDAC2-selectivity of an HDAC inhibitor” Hirokazu Mishima, Yukihiro Itoh, Takashi Kurohara, Takayoshi Suzuki, Naoya Asada, Ken-ichi Kusakabe, Yuko Okamoto. J. Comput. Chem. 2023, 44, in press.
  2. “Catalytic asymmetric synthesis of (‒)-arctigenin using a chiral Ir complex” Rui Jiang, Da-Yang Zhou, Kaori Asano, Takayoshi Suzuki, Takeyuki Suzuki. Tetrahedron 2023, 133, 133287 (Published 26 Jan 2023).
  3. “Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double strand break repair and augments efficacy of temozolomide in glioblastoma” Salvador Alejo, Bridgitte E. Palacios, Prabhakar Pitta Venkata, Yi He, Wenjing Li, Jessica D. Johnson, Yihong Chen, Uday P. Pratap, Sridharan Jayamohan, Kyra Clarke, Yi Zou, Yingli Lv, Korri Weldon, Suryavathi Viswanadhapalli, Zhao Lai, Zhenqing Ye, Yidong Chen, Andrea R. Gilbert, Takayoshi Suzuki, Rajeshwar R. Tekmal, Weixing Zhao, Siyuan Zheng, Ratna K. Vadlamudi, Andrew J. Brenner, Gangadhara R. Sareddy. Neuro Oncol. 2023, 25, in press (Published 16 Jan 2023).
  4. “The discovery of 3,3-dimethyl-1,2,3,4-tetrahydroquinoxaline-1-carboxamide as AMPD2 inhibitors with a novel mechanism of action” Yuki Kitao, Tadataka Saito, Satoshi Watanabe, Yasuhiro Oe, Koichi Takahashi, Tatsuo Akaki, Tsuyoshi Adachi, Satoki Doi, Kenji Yamanaka, Yasutaka Murai, Makoto Oba, Takayoshi Suzuki. Bioorg. Med. Chem. Lett. 2023, 80, 129110 (Published 20 Dec 2022).

依頼講演

  1. 「Chemotherapy triggered by electron beams」Yasunobu Yamashita, Yusa Muroya, Yoshio Mizuta, Yudai Hirai, Kazumasa Minami, Alexei Zhidkov, Yoshihide Honda, Yukihiro Itoh, Yuri Takada, Takahiro Kozawa, Masahiko Koizumi, Tomonao Hosokai, Takayoshi Suzuki. Quantum Beam Application for Sciences and Industries 2023; Apr. 25, 2023 (Osaka)
  2. 「エピジェネティック阻害剤開発の現状と展望」鈴木 孝禎  日本薬学会第143年会； 2023年3月28日（札幌）
  3. 「創薬研究の最前線と量子ビームによる創薬の可能性」鈴木 孝禎  JST 未来社会創造事業 大規模プロジェクト型「レーザー駆動による量子ビーム加速器の開発と実証」－ 電子加速システムの開発 －2022 年度第 2 回シンポジウム； 2023年2月28日（web）
2022

原著論文

  1. “Cancer-Cell-Selective Targeting by Arylcyclopropylamine-Vorinostat Conjugates” Yosuke Ota, Yukihiro Itoh, Takashi Kurohara, Ritesh Singh, Elghareeb E. Elboray, Chenliang Hu, Farzad Zamani, Anirban Mukherjee, Yuri Takada, Yasunobu Yamashita, Mie Morita, Mano Horinaka, Yoshihiro Sowa, Mitsuharu Masuda, Toshiyuki Sakai, Takayoshi Suzuki. ACS Med. Chem. Lett. 2022, 13, 1568–1573 (Published 12 Sep 2022).
  2. “A Novel HDAC1-Selective Inhibitor Attenuates Autoimmune Arthritis by Inhibiting Inflammatory Cytokine Production” Wei Zhe, Naomi Hoshina, Yukihiro Itoh, Toshifumi Tojo, Takayoshi Suzuki, Koji Hase, Daisuke Takahashi. Biol. Pharm. Bull. 2022, 45, 1364–1372 (Published 1 Sep 2022).
  3. “Medicinal Chemistry Research on Targeting Epigenetic Complexes” Yuri Takada, Yasunobu Yamashita, Yukihiro Itoh Takayoshi Suzuki. J. Synth. Org. Chem. Jpn. 2022, 80, 664-675 (Published Jul 2022).
  4. “Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC)” Jiranan Chotitumnavee, Yasunobu Yamashita, Yukari Takahashi, Yuri Takada, Tetsuya Iida, Makoto Oba, Yukihiro Itoh, Takayoshi Suzuki. Chem. Commun. 2022, 58, 4635-4638 (Published 14 Mar 2022).
  5. “Utilization of α and β Epimerization for Synthesis of Both Enantiomers of Enterolactone” Rui Jiang, Ismiyarto, Tsukasa Abe, Da-Yang Zhou, Kaori Asano, Takayoshi Suzuki, Hiroaki Sasai, Takeyuki Suzuki. J. Org. Chem. 2022, 87, 5051-5056 (Published 4 Mar 2022).
  6. “Novel Histone Modifications in Microglia Derived from a Mouse Model of Chronic Pain” Ping Zhang, Jennifer Guergues, Amy R. Alleyne, Thomas J. Cirino, Owen Nadeau, Ariana M. Figueroa, Heather M. Stacy, Takayoshi Suzuki, Jay P. McLaughlin, Stanley M. Stevens, Jr., Bin Liu. Proteomics 2022, 22, e2100137 (Published 26 Jan 2022).
  7. “KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer” Prabhakar Pitta Venkata, Yihong Chen, Salvador Alejo, Yi He, Bridgitte E. Palacios, Ilanna Loeffel, Junhao Liu, Uday P. Pratap, Gabrielle Gray, Sureshkumar Mulampurath Achuthan Pillai, Yi Zou, Zhao Lai, Takayoshi Suzuki, Suryavathi Viswanadhapalli, Srinath Palakurthi, Rajeshwar R. Tekmal, Ratna K. Vadlamudi, Edward Kost, Gangadhara R. Sareddy. Cancer Lett. 2022, 524, 219-231 (Published Jan 2022).

総説

  1. “Recent progress on small molecules targeting epigenetic complexes” Yukihiro Itoh, Yuri Takada, Yasunobu Yamashita and Takayoshi Suzuki. Curr. Opin. Chem. Biol. 2022, 67, 102130. (Published: 28 Feb 2022)

著書

  1. 「ケミカルエピジェネティクスと創薬」鈴木孝禎　遺伝学の百科事典 継承と多様性の源 日本遺伝学会編 丸善出版2022, 10–23.
  2. “Biological behavior of 1,4-benzodiazepines and 1,4-benzothiazepines” Farzad Zamani, Nasrin Zamani, Takayoshi Suzuki, Esmail Doustkhah Benzoziazepine-Based Drug Discovery (Elsevier) 2022, pp 77–124.

特許出願

  1. 「電子ビーム照射装置及び電子ビーム照射方法」細貝 知直、山下 泰信、室屋 裕佐、鈴木 孝禎　特願2022-046567

依頼講演

  1. 「エピジェネティクスを標的とする創薬・ケミカルバイオロジー研究」鈴木 孝禎 第96回日本薬理学会年会； 2022年12月1日（横浜）
  2. 「創薬 NF 検討会における人材育成活動と産学連携研究～解離遅延型阻害薬の新展開～」鈴木 孝禎 第39回メディシナルケミストリーシンポジウム； 2022年11月23日（web）
  3. “Chemical Control of Epigenetics~Discovery of Histone Lysine Demethylase Inhibitors~” Takayoshi Suzuki. Lecture in Global Frontiers in Life Science A, Kyoto University; Jul 6, 2022 (Kyoto)
  4. 「ヒストン修飾を制御する化合物の探索」鈴木 孝禎 第49回日本毒性学会学術年会；2022年7月1日（札幌）
  5. “Discovery of epigenetic enzyme inhibitors by target-guided synthesis” Takayoshi Suzuki. The 142nd Annual Meeting of Pharmaceutical Society of Japan; Mar. 27, 2022 (web).
2021

原著論文

  1. “Identification of novel histone deacetylase 6-selective inhibitors bearing 3,3,3-trifluorolactic amide (TFLAM) motif as a zinc binding group” Takashi Kurohara, Keita Tanaka, Daisuke Takahashi, Satoshi Ueda, Yasunobu Yamashita, Yuri Takada, Hirokazu Takeshima, Shengwang Yu, Yukihiro Itoh, Koji Hase, Takayoshi Suzuki. ChemBioChem 2021, 22, 3158-3163. (Published 05 July 2021)
  2. “Identification of Potent and Selective Inhibitors of Fat Mass Obesity Associated Protein Using a Fragment-Merging Approach” Muthuraj Prakash, Yukihiro Itoh, Yoshie Fujiwara,Yukari Takahashi, Yuri Takada, Paolo Mellini, Elghareeb E. Elboray, Mitsuhiro Terao, Yasunobu Yamashita, Chika Yamamoto, Takao Yamaguchi, Masayuki Kotoku, Yuki Kitao, Ritesh Singh, Rohini Roy, Satoshi Obika, Makoto Oba, Dan Ohtan Wang, and Takayoshi Suzuki. J. Med. Chem. 2021, 64, 15810–15824. (Published: 3 November 2021)
  3. “Ca2+-activated K+ channel KCa1.1 as a therapeutic target to overcome chemoresistance in three-dimensional sarcoma spheroid models” Susumu Ohya, Junko Kajikuri, Kyoko Endo, Hiroaki Kito, Elghareeb Elboray, Takayoshi Suzuki. Cancer Sci. 2021, 112, 3769-3783. (Published: 28 June 2021)
  4. “Catalytic Enantioselective Tishchenko Reaction of meso-Dialdehyde: Catalytic Asymmetric Synthesis of Cedarmycins” Ismiyarto, Nobuki Kishi, Yuki Adachi, Rui Jiang, Takahiro Doi, Da-Yang Zhou, Kaori Asano, Yasushi Obora, Takayoshi Suzuki, Hiroaki Sasai, and Takeyuki Suzuki. RSC Adv. 2021, 11, 11606–11609. (Published: 22 March 2021)
  5. “Discovery of novel tetrahydrobenzo[b]thiophene-3-carbonitriles as histone deacetylase inhibitors” Piyush Gediya, Vivek K. Vyas, Vincenzo Carafa, Nikum Sitwala, Laura Della Torre, Angelita Poziello, Takashi Kurohara, Takayoshi Suzuki, Varalakshmi Raghuraman, K. Suthindhiran, Debarpan Ghosh, Dhiraj Bhatia, Lucia Altucci, Manjunath D. Ghate. Bioorg. Chem. 2021, 110, 104801. (Published: 5 March)
  6. “Design, Synthesis, and Biological Evaluation of Lysine Demethylase 5C Degraders” Tetsuya Iida, Yukihiro Itoh, Yukari Takahashi, Yasunobu Yamashita,　Takashi Kurohara,　Yuka Miyake, Makoto Oba, Takayoshi Suzuki. ChemMedChem 2021, 16, 1609-1618. (Published: 20 January 2021)

総説

  1. “Synthetic RNA Modulators in Drug Discovery“ Farzad Zamani and Takayoshi Suzuki. J. Med. Chem. 2021, 64, 7110-7155. (Published: 1 June 2021)

著書

  1. 「ヒストンアセチル化制御薬」鈴木孝禎　遺伝子医学MOOK 36 エピゲノムで新たな解明が進む「先天性疾患」 2021, pp 210–214.
  2. 「ヒストンの化学修飾とがん」鈴木孝禎　CSJカレントレビュー 生体分子と疾患 日本化学会編2021, pp 46–51.

その他の依頼記事

  1. “Simplifying Submission Requirements for the Journal of Medicinal Chemistry” Craig W. Lindsley, James Barrow, Kelly Chibale, Maria Laura Bolognesi, Stuart Conway, William Denny, Ke Ding, Stefan Laufer, Luhua Lai, Hong Liu, Nouri Neamati, Takayoshi Suzuki, Nicholas Meanwell, Wendy Young. J. Med. Chem. 2021, 64, 7877–7878. (Published: 15 June 2021)
  2. 「モダリティー多様化時代における低分子創薬の新たな視点～KDM5を標的とした創薬化学研究を例として～」伊藤幸裕、鈴木孝禎　ファルマシア2021, 57, 651–655.

依頼講演

  1. “Identification of lysine demethylase inhibitors as candidate therapeutic agents” Takayoshi Suzuki. Pacifichem 2021; Dec. 19, 2021 (web)
  2. 「ヒストン修飾を制御する小分子化合物の探索」鈴木孝禎  第94回 日本生化学会大会；2021年11月3日（web）
  3. 「創薬化学の今と未来」鈴木孝禎  大阪大学理学部 化学・高分子コロキウム講演会；2021年10月18日（web）
  4. 「中枢神経性疾患治療を目指したエピジェネティクス制御化合物の創製」鈴木孝禎  第64回日本神経化学会大会；2021年9月30日（web）
  5. 「エピジェネティクス制御に基づいた創薬化学研究」鈴木孝禎 千里ライフサイエンス振興財団 新適塾「未来創薬への誘い」第53回会合；2021年4月20日（web）
  6. “Chemical Control of Epigenetics~Discovery of Histone Lysine Demethylase Inhibitors~” Takayoshi Suzuki. Lecture in Global Frontiers in Life Science A, Kyoto University; May 19, 2021 (Web)
  7. 「エピジェネティクスを標的とした創薬化学研究」鈴木孝禎 立命館大学薬学部 精密合成化学セミナー（第６回）；2021年3月12日（草津）

国内の発表

  1. KDM5C選択的阻害剤の同定とその抗うつ作用　鈴木孝禎、三宅由花、伊藤幸裕、内田周作　第１４回日本エピジェネティクス研究会年会　P-46 2021年3月30日（web）
  2. Induced-fit 型 HDAC 酵素阻害薬の同定とそのアロステリック作用の解析
    伊藤幸裕、展鵬、東條敏史、鈴木美紀、李頴、内田周作、鈴木孝禎
    日本ケミカルバイオロジー学会　第15回年会 O-29 2021年6月23日（web）
  3. エピジェネティクス関連酵素に対する分解誘導薬の創製
    伊藤幸裕、飯田哲也、Chotitumnavee Jiranan、高橋 ゆかり、山下泰信、黒原崇、三宅由花、大庭誠、鈴木孝禎
    第15回バイオ関連化学シンポジウム　3A-01　2021年9月10日（web）
2020

原著論文

  1. “N+-C-H···O Hydrogen bonds in protein-ligand complexes and their application to drug design” Yukihiro Itoh, Takashi Kurohara, Takayoshi Suzuki. J. Synth. Org. Chem. Jpn. 2020, 78, 1151–1162. (Published: 1 December 2020)
  2. “KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer” Mei Zhou, Prabhakar Pitta Venkat, Suryavathi Viswanadhapalli, Bridgitte Palacios, Salvador Alejo, Yihong Chen, Yi He, Uday Pratap, Yi Zou, Zhao Lai, Takayoshi Suzuki, Andrew Brenner, Rajeshwar R. Tekmal, Ratna K. Vadlamudi, Gangadhara R. Sareddy. Breast Cancer Res. Treat. 2020, 185, 343–357.（Published: 14 October 2020）
  3. “Downregulation of the Ca2+-activated K+ channel KCa3.1 in mouse preosteoblast cells treated with vitamin D receptor agonist” Hiroaki Kito, Haruka Morihiro, Yuka Sakakibara, Kyoko Endo, Junko Kajikuri, Takayoshi Suzuki, Susumu Ohya. Am. J. Physiol. Cell Physiol. 2020, 319, C345–C358.（Published: 28 July 2020）
  4. “Cross-Species Chromatin Interactomes Drive Heterochromatin, Enhancer, and Transcriptional Rewiring in Epstein-Barr Virus Positive Gastric Adenocarcinoma” Atsushi Okabe, Kie Kyon Huang, Keisuke Matsusaka, Masaki Fukuyo, Manjie Xing, Xuewen Ong, Takayuki Hoshii, Genki Usui, Motoaki Seki, Yasunobu Mano, Bahityar Rahmutulla, Teru Kanda, Takayoshi Suzuki, Sun Young Rha, Tetsuo Ushiku, Masashi Fukayama, Patrick Tan, Atsushi Kaneda. Nat. Genet. 2020, 52, 919–930.（Published: 27 July 2020）
  5. “Selective lysine specific demethylase 1 inhibitor, NCL1, could cause testicular toxicity via the regulation of apoptosis” Satoshi Nozaki, Taku Naiki, Aya Naiki-Ito, Shoichiro Iwatsuki, Tomoki Takeda, Toshiki Etani, Takashi Nagai, Keitaro Iida, Takayoshi Suzuki, Satoru Takahashi, Takahiro Yasui, Yukihiro Umemoto. Andrology 2020, 8, 1895–1906.（Published: 29 June 2020）
  6. “Metalloprotein-Catalyzed Click Reaction for In Situ Generation of a Potent Inhibitor” Yuka Miyake, Yukihiro Itoh, Yoshinori Suzuma, Hidehiko Kodama, Takashi Kurohara, Yasunobu Yamashita, Remy Narozny, Yutaro Hanatani, Shusaku Uchida, Takayoshi Suzuki. ACS Catal. 2020, 10, 5383–5392.（Published: 13 April 2020）
  7. “Metabolic-Pathway-Oriented Screening Targeting S-Adenosyl-l-methionine Reveals the Epigenetic Remodeling Activities of Naturally Occurring Catechols” Shusuke Ogihara, Toru Komatsu, Yukihiro Itoh, Yuka Miyake, Takayoshi Suzuki, Kouichi Yanagi, Yusuke Kimura, Tasuku Ueno, Kenjiro Hanaoka, Hirotatsu Kojima, Takayoshi Okabe, Tetsuo Nagano, Yasuteru Urano. J. Am. Chem. Soc. 2020, 142, 21–26.（Published: 23 December 2019）
  8. “Possible contribution of inflammation-associated hypoxia to increased K2P1 K+ channel expression in CD4+ T cells of the mouse model for inflammatory bowel disease” Kyoko Endo, Hiroaki Kito, Ryo Tanaka, Junko Kajikuri, Satoshi Tanaka, Elghareeb E. Elboray, Takayoshi Suzuki, Susumu Ohya. Int. J. Mol. Sci. 2020, 21, 38.（Published: 19 December 2019）
  9. “Discovery of gamma-mangostin from Garcinia mangostana as potent and selective natural SIRT2 inhibitor” Keng Yoon Yeong, Kooi Yeong Khaw, Yukari Takahashi, Yukihiro Itoh, Vikneswaran Murugaiyah, Takayoshi Suzuki. Bioorg. Chem. 2020, 94, 103403.（Published:4 November 2019）
  10. “LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia” Goichi Tatsumi, Masahiro Kawahara, Ryusuke Yamamoto, Masakatsu Hishizawa, Katsuyuki Kito, Takayoshi Suzuki, Akifumi Takaori-Kondo, Akira Andoh. Leukemia 2020, 34, 746–758.（Published: 01 November 2019）
  11. “Early sirtuin 2 inhibition prevents age-related cognitive decline in a senescence accelerated mouse model”　Teresa Diaz-Perdigon, Borja Belloch, Ana Ricobaraza, Elghareeb Elboray, Takayoshi Suzuki, Rosa Tordera, Elena Puerta. Neuropsychopharmacolgy 2020, 45, 347–357.（Published: 30 August 2019）

著書

  1. “Epigenetic Control Using Small Molecules in Cancer” Tomohiro Kozako, Yukihiro Itoh, Shin-ichiro Honda, Takayoshi Suzuki Approaching Complex Diseases (Springer) 2020, pp 111–148.（Published: April 2020）
  2. “Lysine-Specific Histone Demethylases 1/2 (LSD1/2) and Their Inhibitors” Takayoshi Suzuki Chemical Epigenetics (Springer) 2020, pp 197–219. （Published: April 2020）

特許

  1. 「炎症性腸疾患処置剤」長谷耕二、高橋大輔、鈴木 孝禎、黒原 崇、上田 聡、田中 啓太　特願2020-064635.（出願: 2020年 3月31日）

その他の依頼記事

  1. 「ヒストンメチル化酵素・脱メチル化酵素阻害薬」鈴木孝禎　医学のあゆみ 2020, 272, 123–128.（2020年 1月）
  2. 「エピゲノム修飾薬」鈴木孝禎　遺伝子医学 2020, 31, 74–79.（2020年 1月）
  3. 「標的タンパク質自身に阻害薬をつくらせる！―短時間で薬の候補を見つける創薬手法」伊藤幸裕、鈴木孝禎　化学 2020, 75, 40–44.（2020年 8月）
  4. “Excellence in Medicinal Chemistry Research from Japan” Shaomeng Wang, Gunda Georg, Minoru Ishikawa, Tomohiko Ohwada, Satoshi Shuto, Takayoshi Suzuki. J. Med. Chem. 2020, 63, 8877–8879.（Published: 25 August 2020）
  5. 「DNAとヒストンのメチル化を標的とした抗がん剤の開発」鈴木孝禎　実験医学 増刊 2020, 38, 2476–2481. （2020年 9月）
  6. 「ヒストンメチル化酵素・脱メチル化酵素阻害薬」鈴木孝禎　別冊・医学のあゆみ エピジェネティクスと疾患 2020, pp 123–128.（2020年11月）

依頼講演

  1. “Identification of Epigenetic Inhibitors by Target-Guided Synthesis” Academia Sinica-Osaka University Symposium 2020; Nov 17, 2020 (Web)
  2. “Chemical Control of Epigenetics~Discovery of Histone Lysine Demethylase Inhibitors~” Takayoshi Suzuki; Lecture in Global Frontiers in Life Science A, Kyoto University; Jul 15, 2020 (Kyoto)

国内の発表

  1. 金属イオン結合型in situクリック反応によるKDM5C阻害薬の同定　伊藤幸裕、三宅由花、鈴間喜教、児玉英彦、内田周作、鈴木孝禎　第14回バイオ関連化学シンポジウム　1A-08　2020年9月7日　（web）
2019

原著論文

  1. “Genome-wide ChIP-seq data with a transcriptome analysis reveals the groups of genes regulated by histone demethylase LSD1 inhibition in esophageal squamous cell carcinoma cells” Isamu Hoshino, Masahiko Takahashi, Yasunori Akutsu, Kentaro Murakami, Yasunori Matsumoto, Hiroshi Suito, Nobufumi Sekino, Aki Komatsu, Keiko Iida, Takayoshi Suzuki, Itsuro Inoue, Fumitaka Ishige, Yosuke Iwatate, Hisahiro Matsubara. Oncol. Lett. 2019, 18, 872–881.（Published: May 13, 2019）

依頼講演

  1. “Identification of Epigenetic Inhibitors by Target-Guided Synthesis” Academia Sinica-Osaka University Symposium 2020; Nov 17, 2020 (Web)
  2. “Discovery of Epigenetic Inhibitors Using Target-Guided Synthesis” Takayoshi Suzuki; The 4th Roundtable Meeting on Chemical Probe Research Hub; Nov 19, 2019 (Sendai)
  3. “Discovery of histone demethylase inhibitors: drug design focusing on C-H···O hydrogen bonds” Takayoshi Suzuki; The 6th International Cancer Epigenomics Symposium 2019, Seminar in Hematologic Malignancies and Epigenetics; Sep 13, 2019 (Chiba)
  4. “Chemical Control of Epigenetics~Discovery of Histone Lysine Demethylase Inhibitors and Histone Deacetylase Inhibitors~” Takayoshi Suzuki; Lecture in Global Frontiers in Life Science A, Kyoto University; Jun 26, 2019 (Kyoto)

京都府立医科大学（2011-2019.06）での研究業績